EVLO logo

Evelo Biosciences (EVLO) Company Overview

Profile

Full Name:

Evelo Biosciences, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 8, 2018

Indexes:

Not included

Description:

Evelo Biosciences is a biotechnology company focused on developing treatments for diseases using a unique approach. They create therapies based on the gut microbiome, which is the collection of microorganisms in our intestines. Their goal is to improve health by harnessing the power of these microbes.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 24, 2025

Recent annual earnings:

Feb 24, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 30, 2023

Analyst ratings

Recent major analysts updates

Oct 18, 23 TD Cowen
Market Perform
Jul 26, 23 Morgan Stanley
Equal-Weight
Feb 15, 23 Morgan Stanley
Equal-Weight
Nov 16, 22 Chardan Capital
Neutral
Sep 9, 22 Morgan Stanley
Equal-Weight
Aug 24, 22 Morgan Stanley
Equal-Weight
Aug 15, 22 Chardan Capital
Buy
Nov 2, 21 JMP Securities
Market Outperform
Nov 1, 21 Chardan Capital
Buy
Jun 23, 21 JMP Securities
Market Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Evelo Biosciences?
  • Does Evelo Biosciences pay dividends?
  • What sector is Evelo Biosciences in?
  • What industry is Evelo Biosciences in?
  • What country is Evelo Biosciences based in?
  • When did Evelo Biosciences go public?
  • Is Evelo Biosciences in the S&P 500?
  • Is Evelo Biosciences in the NASDAQ 100?
  • Is Evelo Biosciences in the Dow Jones?
  • When was Evelo Biosciences's last earnings report?
  • When does Evelo Biosciences report earnings?
  • Should I buy Evelo Biosciences stock now?

What is the ticker symbol for Evelo Biosciences?

The ticker symbol for Evelo Biosciences is NASDAQ:EVLO

Does Evelo Biosciences pay dividends?

No, Evelo Biosciences does not pay dividends

What sector is Evelo Biosciences in?

Evelo Biosciences is in the Healthcare sector

What industry is Evelo Biosciences in?

Evelo Biosciences is in the Biotechnology industry

What country is Evelo Biosciences based in?

Evelo Biosciences is headquartered in United States

When did Evelo Biosciences go public?

Evelo Biosciences's initial public offering (IPO) was on May 8, 2018

Is Evelo Biosciences in the S&P 500?

No, Evelo Biosciences is not included in the S&P 500 index

Is Evelo Biosciences in the NASDAQ 100?

No, Evelo Biosciences is not included in the NASDAQ 100 index

Is Evelo Biosciences in the Dow Jones?

No, Evelo Biosciences is not included in the Dow Jones index

When was Evelo Biosciences's last earnings report?

Evelo Biosciences's most recent earnings report was on Feb 24, 2025

When does Evelo Biosciences report earnings?

The date for Evelo Biosciences's next earnings report has not been announced yet

Should I buy Evelo Biosciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions